Remel Inc.

Remel Inc., doing business as Thermo Fisher Scientific Remel Products, supplies specialized microbiology laboratory consumables and diagnostic equipment—primarily Sensititre antimicrobial susceptibility testing (AST) systems, blood culture media, diagnostic panels, and related reagents—to federal health and research agencies as a prime contractor on full-and-open, firm fixed-price delivery orders and indefinite delivery contracts. The company is a foreign-owned subsidiary of Thermo Fisher Scientific Inc., headquartered in Lenexa, Kansas, and competes without set-asides across all federal customer relationships.

Remel's recent federal award footprint spans 8,057 prime contracts and IDIQs with $722 million in combined potential value, of which $491.3 million is obligated. The vendor works exclusively on full-and-open procurements and holds no subcontract positions; all awards are prime contractor relationships. Activity has averaged 15 to 27 awards per year over the past five years, with thirteen awards recorded in 2026 to date. Eight awards reaching completion in the next twenty-four months carry combined potential value of $981 thousand and represent recompete exposure across multiple customer agencies.

Customer concentration is diffuse, with Remel serving fifty-eight federal agencies. The top five customers by combined potential value—the FDA, USDA Office of Administrative Services, Veterans Affairs VISN 20, CDC Pittsburgh, and Army Medical Command—account for only 4% of the vendor's total potential value, indicating broad portfolio diversification. By award count, the Defense Logistics Agency Troop Support Medical leads with 157 awards ($384 thousand), followed by FDA with 74 awards ($11.8 million), and CDC Pittsburgh with 66 awards ($3.6 million). The FDA and USDA Office of Administrative Services rank highest by dollar magnitude, reflecting reliance on higher-value indefinite delivery vehicles that support national antimicrobial resistance monitoring and food safety missions.

Remel holds seven named indefinite delivery contracts totaling approximately $8.6 million in ceiling value across civilian agencies. The FDA single-award IDIQ of $2.5 million (through March 20, 2027) anchors the portfolio for Sensititre-compatible supplies supporting the National Antimicrobial Resistance Monitoring System and veterinary regulatory science; sixteen task orders totaling $1.14 million have drawn against this vehicle since 2022. A newly awarded FDA IDIQ for QuantStudio 5 real-time PCR systems carries $1.9 million in ceiling value through February 28, 2031 and requires 20 systems in the base year with training and deployment to eleven FDA laboratory locations. USDA's $600,000 IDV (through September 4, 2027) for AST supplies supporting NARMS and the Eastern Laboratory has generated approximately $130,611 in delivery orders. The Defense Health Agency holds a $2.36 million IDIQ (through May 21, 2029) for Sensititre consumables in support of Walter Reed Army Institute of Research. Veterans Affairs maintains two IDIQs totaling $1.75 million combined ceiling ($1.25 million VISN 20, awarded January 1, 2026, through December 31, 2030; and $500,000 VISN 20 blood culture media, awarded November 1, 2025, through October 31, 2029). The vendor also holds a $400,000 USDA FSIS IDIQ (through March 31, 2028) for analytical testing supplies and food safety programs. The majority of Remel's federal revenue flows through the GSA Federal Supply Schedule (V797P5588X), which carries 4,227 task orders and $6.4 million in combined potential value, serving DLA Troop Support Medical and other federal customers on a streamlined ordering basis.

Remel's work concentrates in NAICS 325413 (In Vitro Diagnostic Substance Manufacturing), which represents 4,530 of the 8,057 awards, with secondary concentration in analytical laboratory instrument manufacturing and medical equipment repair and maintenance. PSC codes 6550 (In Vitro Diagnostic Substances, Reagents, Test Kits, and Sets) and 6610 (Laboratory Equipment and Supplies) dominate the portfolio, accounting for 3,369 and 3,185 awards respectively. Representative recent contracts include the FDA's $1.9 million QuantStudio 5 PCR IDIQ with base-year delivery of twenty systems to eleven laboratories; a $2.5 million FDA IDIQ for Sensititre-compatible supplies supporting NARMS, with task orders routinely issued for $40,000–$96,000 each; a USDA $217,514 definitive contract for AST Trek equipment maintenance (base plus four option years through July 31, 2027); Veterans Affairs delivery orders for blood culture media and automated microbial detection systems ($98,571 ceiling) and AST reagent agreements ($131,929 ceiling through December 31, 2026); CDC task orders for Sensititre service and consumables, including a $228,795 five-year annual service agreement for SDG Gold Sensititre support through September 2029; and numerous Defense Health Agency and Army Medical Command orders for Sensititre dry panels and maintenance services supporting clinical laboratory operations.

The source characterizes Remel as a foreign-owned, for-profit subsidiary of Thermo Fisher Scientific with substantial federal presence, noting its "established position as a critical supplier of microbiology laboratory products and diagnostic consumables to federal health and research agencies" and extensive track record supporting antimicrobial resistance surveillance, food safety, and clinical diagnostic missions. The company's federal contracting footprint reflects concentration in scientific equipment supply to health and defense laboratories rather than broad professional services or IT capabilities.